Paper Details

  1. Home
  2. Paper Details

Traitement médical des carcinomes basocellulaires avancés: Medical treatment of advanced basal cell carcinoma

Author: Basset-SeguinN

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Vismodegib and sonidegib are targeted anti-SMO drugs that are effective in treating advanced basal cell carcinoma (BCC). Vismodegib is indicated for locally advanced and metastatic BCC, while sonidegib is only indicated for locally advanced BCC. The objective response rate (ORR) for vismodegib was 47.6% at 21 months, while the ORR for sonidegib was 56.1% at 18 months. Although both treatments have a similar adverse event profile, most patients discontinue treatment due to side effects. Future hopes rely on immunotherapy for resistant or poorly tolerated cases.
Paper Details　
Original Abstract of the Article :
Until recently, advanced BCC were only accessible to a highly morbid surgery not necessarily proving to be carcinologic, and leaving terrible dysmorphic sequelae hard to accept by the patient. Another possibility, the only one in case of metastatic BCC, was chemotherapy which efficacy has never been...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0151-9638(18)31257-2

データ提供：米国国立医学図書館（NLM）

Targeted Therapy for Basal Cell Carcinoma: A New Frontier

Basal cell carcinoma (BCC) is a common type of skin cancer that can be difficult to treat, especially in advanced cases. This research explores the potential of targeted therapy, specifically drugs that inhibit the sonic hedgehog pathway, for treating advanced BCC. The study examines the clinical efficacy and safety of two targeted anti-SMO drugs: vismodegib and sonidegib.

Targeted Therapy: A Promising Approach for BCC

The results showed that both vismodegib and sonidegib were effective in treating locally advanced and metastatic BCC. While both treatments share a similar adverse event profile, most patients discontinue treatment in the long term due to side effects. This highlights the need for further research to develop more tolerable and effective therapies.

Managing BCC: A Multidisciplinary Approach

The study underscores the importance of a multidisciplinary approach to managing BCC, involving dermatologists, oncologists, and other healthcare professionals. Just as a camel caravan needs to rely on the expertise of its members, patients should seek care from a team of specialists to develop an optimal treatment plan.

Dr.Camel's Conclusion

This research represents a significant advancement in the treatment of advanced BCC. Like a desert oasis providing hope to weary travelers, targeted therapy offers new possibilities for patients battling this challenging disease.

Date :
  1. Date Completed 2019-05-09
  2. Date Revised 2020-11-13
Further Info :

Pubmed ID

30477683

DOI: Digital Object Identifier

10.1016/S0151-9638(18)31257-2

Related Literature

Article Analysis
・Side Effects of sonidegib
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.